Related Experiment Videos
Is thrombolytic therapy safe during active menstruation?
1Department of Medicine, Sinai Hospital of Baltimore, MD 21215, USA.
The Journal of Emergency Medicine
|May 1, 1995
Summary
Thrombolytic therapy, including tissue plasminogen activator (tPA), is safe for women experiencing acute myocardial infarction during normal menstruation. This case study suggests menstruation is not a contraindication for life-saving treatments.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Acute myocardial infarction (AMI) requires prompt treatment.
- Thrombolytic therapy is a critical intervention for AMI.
- Safety concerns exist regarding thrombolytic use during menstruation.
Observation:
- A 39-year-old female presented with AMI symptoms on the fourth day of menstruation.
- She received thrombolytic therapy (tPA) and heparin.
- Menstrual bleeding was minimally prolonged; hemoglobin remained stable after an initial dilutional drop.
Findings:
- The patient tolerated thrombolytic therapy well despite active menstruation.
- Minimal impact on hemoglobin levels was observed, attributed to fluid administration.
- No contraindication to thrombolytic therapy during normal menstruation was identified.
Implications:
- This case supports the use of thrombolytic therapy in menstruating women with AMI.
- Further research may clarify guidelines for thrombolytic use during menstruation.
- Prompt treatment for AMI should not be delayed due to menstruation.